Mercer Global Advisors Inc Bio N Tech Se Transaction History

Mercer Global Advisors Inc

$39.5 Billion
Q2 2024

A detailed history of Mercer Global Advisors Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Mercer Global Advisors Inc holds 3,283 shares of BNTX stock, worth $390,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,283

Previous 9,555 65.64%

Holding current value

$390,677

Previous $881,000 70.15%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$80.36 - $102.87 $504,017 - $645,200	-6,272 Reduced 65.64%	3,283 $263,000
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $78,640 - $99,317	884 Added 10.19%	9,555 $881,000
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $84,546 - $104,857	930 Added 12.01%	8,671 $915,000
Q3 2023 Nov 13, 2023	BUY	$98.5 - $125.08 $204,289 - $259,415	2,074 Added 36.6%	7,741 $841,000
Q2 2023 Aug 14, 2023	SELL	$102.58 - $129.66 $10,668 - $13,484	-104 Reduced 1.8%	5,667 $611,000
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $62,878 - $78,832	-513 Reduced 8.16%	5,771 $718,000
Q4 2022 Feb 08, 2023	BUY	$118.43 - $186.05 $70,821 - $111,257	598 Added 10.52%	6,284 $944,000
Q3 2022 Nov 15, 2022	BUY	$127.65 - $183.11 $76,207 - $109,316	597 Added 11.73%	5,686 $767,000
Q2 2022 Aug 10, 2022	BUY	$123.25 - $186.24 $128,303 - $193,875	1,041 Added 25.72%	5,089 $759,000
Q1 2022 May 10, 2022	BUY	$126.25 - $231.85 $96,455 - $177,133	764 Added 23.26%	4,048 $690,000
Q4 2021 Feb 04, 2022	BUY	$216.64 - $362.52 $549,832 - $920,075	2,538 Added 340.21%	3,284 $847,000
Q3 2021 Nov 10, 2021	SELL	$205.93 - $447.23 $60,131 - $130,591	-292 Reduced 28.13%	746 $204,000
Q2 2021 Aug 10, 2021	BUY	$113.32 - $241.49 $117,626 - $250,666	1,038 New	1,038 $232,000

Others Institutions Holding BNTX

# of Institutions

328

Shares Held

40.6M

Call Options Held

845K

Put Options Held

1.23M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.9B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.

Account

Mercer Global Advisors Inc Bio N Tech Se Transaction History